d1447a31-64bb-4e70-ae50-eeff7a605f38
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.320
- SPERMATOGENESIS+0.210
- PROTEIN_SECRETION+0.150
- ANDROGEN_RESPONSE+0.100
- KRAS_SIGNALING_DN+0.090
- TGF_BETA_SIGNALING+0.060
- PANCREAS_BETA_CELLS+0.050
- HEDGEHOG_SIGNALING+0.020
- KRAS_SIGNALING_UP-0.050
- BILE_ACID_METABOLISM-0.060
Top 10 suppressed
- MYC_TARGETS_V2-0.640
- OXIDATIVE_PHOSPHORYLATION-0.570
- DNA_REPAIR-0.540
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.540
- MYC_TARGETS_V1-0.510
- CHOLESTEROL_HOMEOSTASIS-0.480
- INTERFERON_ALPHA_RESPONSE-0.470
- P53_PATHWAY-0.450
- ADIPOGENESIS-0.440
- FATTY_ACID_METABOLISM-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.976 |
| 2 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.960 |
| 3 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.951 |
| 4 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.950 |
| 5 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.946 |
| 6 | e356598b-7611-492a-98ed-ef2ec1b77b7a | — | — | 0.939 |
| 7 | ed8896f8-24ef-43a4-ace6-ed9353bd11c2 | — | — | 0.935 |
| 8 | SRR627455 | GTEX | — | 0.934 |
| 9 | SRR627449 | GTEX | — | 0.926 |
| 10 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |